Table 1.
Investigation at baseline and follow-up
| Investigations | Normal range (unit) |
At admission | Day 17 of admission | First Follow-up (two weeks of therapy) |
Second follow-up (six weeks of therapy) |
| Haemoglobin | 120–140 (g/L) | 107 g/L | 81 g/L | 107 g/L | Not done |
| Total leucocyte counts | 4–11 (109/L) | 8.3 | 5.8 | 7.4 | |
| Differential leucocyte count | (%) | ||||
| Neutrophils (%) | 55–60 | 25.8 | 17 | 25.3 | |
| Lymphocytes (%) | 35–40 | 65.4 | 74 | 62.7 | |
| Monocytes (%) | 1–5 | 08 | 7 | 8.5 | |
| Platelets | 150–450 (109/L) | 5.7 | 3.69 | 3.48 | |
| C-reactive protein (CRP) | <0.5 (mg/L) | 25.9 mg/L | Not done | 0.32 mg/L | |
| Erythrocyte sedimentation rate (ESR) | 0–20 (mm/hour) | 60 mm/hour | 07 mm/hour | ||
| Liver function test | |||||
| Alanine aminotransferase (ALT) | 0–20 (U/L) | 168 U/L | 168 U/L | 179 U/L | 78 U/L |
| Aspartate aminotransferase (AST) | 0–20 (U/L) | 270 U/L | 402 U/L | 240 U/L | 90 U/L |
| Alkaline phosphate (ALP) | 250–450 (U/L) | 427 U/L | 707 U/L | 753 U/L | 255 U/L |
| Total bilirubin | 0–1.2 (mg/dL) | 0.41 mg/dL | 0.47 mg/dL | 0.5 mg/dL | 0.34 mg/dL |
| Triglyceride | <265 (mg/dL) | Not done | 573 mg/dL | 541 mg/dL | 196 mg/dL |
| Fibrinogen | <1.5 (g/L) | 2.58 g/L | 3.78 g/L | 1.86 g/L | |
| Ferritin | <500 (mcg/L) | 1650 mcg/L | 827.5 mcg/L | 37.0 mcg/L | |